Deuterated etifoxine is a small molecule commercialized by Atai Life Sciences, with a leading Phase I program in Post Partum Depression (Maternal Depression / Postnatal Depression). According to Globaldata, it is involved in 8 clinical trials, of which 2 were completed, 3 are ongoing, and 3 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Deuterated etifoxine’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Deuterated etifoxine is expected to reach an annual total of $183 mn by 2036 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Deuterated etifoxine Overview
Deuterated etifoxine is under development for the treatment of neuropathic and inflammatory pain, multiple sclerosis, epilepsy, generalized anxiety disorder, social anxiety disorder(SAD), major depressive disorder(MDD), treatment resistant depression(TRD), post partum depression (PPD), essential tremor, depression, autism spectrum disorders(ASD) and pediatric epilepsy, Alzheimer’s disease, stroke, traumatic brain injury, nerve/spinal cord injury and retinal/macular degeneration. Deuterated etifoxine is a version of racemic etifoxine. It is administered through oral route. It is developed based on allosteric modulation technology. It acts by targeting GABAA receptors and TSPO. D-etifoxine is a new chemical entity (NCE).
Atai Life Sciences Overview
Atai Life Sciences (ALS) is a biotechnology company that develops innovative treatments for addressing depression, anxiety, addiction, other unmet medical needs and mental health disorders. It aims to accelerate the development of new medicines across all its companies to receive clinically meaningful, and sustained behavioral change in mental health of patients. The company has its offices in New York, London and Berlin. ALS is headquartered in Berlin, Germany.
The company reported revenues of (US Dollars) US$20.4 million for the fiscal year ended December 2021 (FY2021). The operating loss of the company was US$136.3 million in FY2021, compared to an operating loss of US$104.7 million in FY2020. The net loss of the company was US$167.8 million in FY2021, compared to a net loss of US$169.8 million in FY2020.
For a complete picture of Deuterated etifoxine’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.